Metastatic Renal Cell Carcinoma Change Vascularity | Zendy

Takeshi Azuma | Zendy; Yukihide Matayoshi | Zendy; Yohsuke Sato | Zendy; Yujiro Sato | Zendy; Yasushi Nagase | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Metastatic Renal Cell Carcinoma Change Vascularity

Author(s) -

Takeshi Azuma,

Yukihide Matayoshi,

Yohsuke Sato,

Yujiro Sato,

Yasushi Nagase

Publication year - 2012

Publication title -

case reports in urology

Language(s) - English

Resource type - Journals

eISSN - 2090-696X

pISSN - 2090-6978

DOI - 10.1155/2012/654617

Subject(s) - vascularity , medicine , renal cell carcinoma , targeted therapy , oncology , pathology , cancer

Several molecular targeted agents have been approved for clinical use for metastatic renal cell carcinoma (mRCC). A case of a 32-year-old woman with mRCC is presented. These tumors could change vascularity by administration of molecular agents. We could select a drug timely based on findings of computed tomography. To our knowledge, this is the first report that tumor's character change induced by molecular targeted agents can be detected and the efficacy of molecular targeted agents can be predicted.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research